Daiwa Securities Group
LYEL icon

Daiwa Securities Group’s Lyell Immunopharma LYEL Stock Holding History

Daiwa Securities Group’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-45
Closed -$1K – 1333
2025
Q4 		$1K Hold
45
– – ﹤0.01% 1348
2025
Q3 		$1K Hold
45
– – ﹤0.01% 1311
2025
Q2 		$0 Sell
45
-1
-2% -$9 ﹤0.01% 1324
2025
Q1 		$0 Hold
46
– – ﹤0.01% 1303
2024
Q4 		$1K Hold
46
– – ﹤0.01% 1257
2024
Q3 		$1K Hold
46
– – ﹤0.01% 1251
2024
Q2 		$1K Hold
46
– – ﹤0.01% 1292
2024
Q1 		$2K Hold
46
– – ﹤0.01% 1271
2023
Q4 		$2K Hold
46
– – ﹤0.01% 1274
2023
Q3 		$1K Hold
46
– – ﹤0.01% 1259
2023
Q2 		$3K Hold
46
– – ﹤0.01% 1221
2023
Q1 		$2K Hold
46
– – ﹤0.01% 1220
2022
Q4 		$3K Hold
46
– – ﹤0.01% 1199
2022
Q3 		$7K Hold
46
– – ﹤0.01% 1146
2022
Q2 		$6K Buy
46
+11
+31% +$1.12K ﹤0.01% 1161
2022
Q1 		$4K Hold
35
– – ﹤0.01% 1197
2021
Q4 		$5K Buy
+35
New +$7.81K ﹤0.01% 1199

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Daiwa Securities Group's LYEL Position: Q1 2026 in Review

Daiwa Securities Group sold out of Lyell Immunopharma (LYEL) in Q1 2026, closing a stake of 45 shares — an estimated $1K sold.

Daiwa Securities Group first reported a position in LYEL in Q4 2021 and held it in 17 quarters. The position peaked at $7K in Q3 2022. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • Daiwa Securities Group reported no remaining Lyell Immunopharma position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 45 Lyell Immunopharma shares in Q1 2026, an estimated $1K.
  • Daiwa Securities Group first reported a position in Lyell Immunopharma in Q4 2021 and held it in 17 quarters.
  • Daiwa Securities Group's Lyell Immunopharma position peaked at $7K in Q3 2022.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.